论文部分内容阅读
目的探讨瑞舒伐他汀对大鼠糖尿病性心肌病(DCM)的影响。方法将雄性Wistar大鼠50只随机分为正常对照组(n=8)、DCM组(n=21)和DCM+瑞舒伐他汀组(n=21)。DCM组和DCM+瑞舒伐他汀组腹腔注射链脲佐菌素(STZ)建立DCM大鼠模型,DCM+瑞舒伐他汀组大鼠每天以瑞舒伐他汀20mg/kg灌胃,20周后评价各组的体质量、空腹血糖、空腹胰岛素、甘油三酯及胆固醇。采用彩色多普勒超声心动图仪观测左室舒张末期内径(LVIDd)、左室收缩末期内径(LVIDs)、短轴缩短率(FS)及射血分数(EF),二尖瓣及三尖瓣瓣膜返流情况、二尖瓣口E波最大速度、A波最大速度、E/A的比值、E波减速时间(EDT′)、等容舒张时间(IVRT′)及主动脉血流最大速度(APV)等改变。结果①注射STZ1周后,与正常对照组相比,DCM组和DCM+瑞舒伐他汀组大鼠体质量均显著升高(P均<0.05),空腹胰岛素、血清胆固醇及甘油三酯均明显升高(P<0.01,P<0.05);实验末,与正常对照组相比,DCM组和DCM+瑞舒伐他汀组大鼠体质量显著下降(P均<0.01),空腹胰岛素水平明显降低(P均<0.05),空腹血糖及甘油三酯水平显著升高(P均<0.01),DCM组胆固醇水平显著升高(P<0.01);②超声心动图显示,与正常对照组相比,DCM组和DCM+瑞舒伐他汀组大鼠实验末LVIDd值及LVIDs值明显增加(P均<0.01),二尖瓣和三尖瓣瓣膜返流发生率显著增加(P均<0.05),E/A比值及LVEF降低(P均<0.01);DCM+瑞舒伐他汀组大鼠LVIDd值及LVIDs值较DCM组减小(P均<0.05),房室瓣瓣膜返流发生率减少(P均<0.05),E/A比值及EF升高(P均<0.05)。结论瑞舒伐他汀对DCM大鼠的心功能和心肌重构有一定改善作用。
Objective To investigate the effect of rosuvastatin on diabetic cardiomyopathy (DCM) in rats. Methods Fifty male Wistar rats were randomly divided into normal control group (n = 8), DCM group (n = 21) and DCM + rosuvastatin group (n = 21). DCM group and DCM + rosuvastatin group were given intraperitoneal injection of streptozotocin (STZ) to establish DCM rat model. Rats in DCM + rosuvastatin group were orally administered with rosuvastatin 20 mg / kg daily for 20 weeks Group body mass, fasting blood glucose, fasting insulin, triglycerides and cholesterol. Left ventricular end-diastolic dimension (LVIDd), left ventricular end-systolic dimension (LVIDs), short axis shortening (FS) and ejection fraction (EF) were measured by color Doppler echocardiography. Mitral and tricuspid valves Mitral regurgitation, mitral valve regurgitation, maximal E-wave velocities, maximum A wave velocity, E / A ratio, E wave deceleration time (EDT), isovolumic relaxation time (IVRT) and aortic flow maximal velocity APV) and other changes. Results ① After 1 week of STZ injection, the body weight of rats in DCM group and DCM + rosuvastatin group were significantly higher than those in normal control group (all P <0.05), fasting insulin, serum cholesterol and triglyceride were significantly increased (P <0.01, P <0.05). Compared with the normal control group, the body weight of rats in DCM group and DCM + rosuvastatin group decreased significantly at the end of the experiment (P <0.01), and the fasting insulin level decreased significantly (All P <0.05), fasting blood glucose and triglyceride levels were significantly higher (P <0.01), DCM group cholesterol levels were significantly higher (P <0.01); ② echocardiography showed that compared with the normal control group, DCM group LVIDd and LVIDs were significantly increased in both DCM and rosuvastatin groups (all P <0.01), and the rates of mitral and tricuspid regurgitation were significantly increased (P <0.05). The E / A ratio (P <0.01). LVIDd and LVIDs in DCM + rosuvastatin group were lower than those in DCM group (all P <0.05), and the incidence of valvular regurgitation in atrioventricular valve decreased (P <0.05) , E / A ratio and EF (P <0.05). Conclusion Rosuvastatin can improve cardiac function and myocardial remodeling in DCM rats.